AMGEN PRESENTS LATE - BREAKING PHASE 2 OLPASIRAN DATA AT ESC 2023
A new study of a small interfering RNA (siRNA) has revealed lasting effect on cholesterol (a) in patients' Lp(a), according to data from the final analysis of the latest trial of an anti-inflammatory drug in the US.
Source: prnewswire.comPublished on 2023-08-26
Related news
- In Carbon Credits We Trust : A Pragmatic Approach to Scaling Up the Voluntary Market
- Covid - 19 Has Dimmed the Clean Power Market
- Climate Research Shouldnt Be Funded by Fossil Fuel Companies
- SEC Proposes ESG Disclosure Requirements for Investment Advisers | Faegre Drinker Biddle & Reath LLP
- Environmental advocates expand Federal Court case against Santos
- Fisher Asset Management LLC Decreases Stock Holdings in MSCI Inc . ( NYSE : MSCI )
- Arch Resources Publishes 2023 Sustainability Report
- The Rise Of Plastic Offset Schemes , Dearth Of Corporate Carbon Disclosures , And A Chat About Planting Trees
- The benefits of being half green
- More Than 75 % of Organizations Have Experienced At least One Attack Related to Poor Endpoint Device Management – Consumer Electronics Net
- ASOS , Boohoo and Asda investigated over fashion green claims
- ESG investing : Dont throw the baby out with the bathwater | Opinion | Eco - Business
- Press Release | COP27 : Groups warn of severe climate and human rights risk of new hydropower dams and schemes
- Sustainable Aviation Buyers Alliance Announces Aviation Decarbonization First , With Collective Purchase of Sustainable Aviation Fuel Certificates
- Can Institutional Investors Take a Cue From Endowments and Foundations ?